Synthesis of Carfentanil Amide Opioids Using the Ugi Multicomponent Reaction by Váradi, András et al.
Subscriber access provided by Yale University Library
ACS Chemical Neuroscience is published by the American Chemical Society. 1155
Sixteenth Street N.W., Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works
produced by employees of any Commonwealth realm Crown government in the course
of their duties.
Article
Synthesis of carfentanil amide opioids using the Ugi multicomponent reaction
Andras Varadi, Travis C Palmer, Nathan Haselton, Daniel Afonin, Joan J Subrath, Valerie LeRouzic,
Amanda Hunkele, Gavril W. Pasternak, Gina F Marrone, Attila Borics, and SUSRUTA MAJUMDAR
ACS Chem. Neurosci., Just Accepted Manuscript • DOI: 10.1021/acschemneuro.5b00137 • Publication Date (Web): 06 Jul 2015
Downloaded from http://pubs.acs.org on July 9, 2015
Just Accepted
“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted
online prior to technical editing, formatting for publication and author proofing. The American Chemical
Society provides “Just Accepted” as a free service to the research community to expedite the
dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts
appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been
fully peer reviewed, but should not be considered the official version of record. They are accessible to all
readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered
to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published
in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just
Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor
changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers
and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors
or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
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Amanda Hunkelea, Gavril W. Pasternaka, Gina F. Marronea, Attila Boricsb and Susruta 
Majumdara,* 
aDepartment of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New 
York, NY 10065 (USA) 
bInstitute of Biochemistry, Biological Research Centre, Hungarian Academy of Sciences, 
Temesvári krt. 62, Szeged, Hungary H-6726 
Abstract – We report a novel approach to synthesize carfentanil amide analogs utilizing the isocyanide-
based four-component Ugi multicomponent reaction. A small library of bis-amide analogs of carfentanil 
was created using N-alkylpiperidones, aniline, propionic acid and various aliphatic isocyanides. Our lead 
compound showed high affinity for mu (MOR) and delta opioid receptors (DOR) with no appreciable 
affinity for kappa (KOR) receptors in radioligand binding assays. The compound was found to be a mixed 
MOR agonist / partial DOR agonist in [35S]GTPγS functional assays, and it showed moderate analgesic 
potency in vivo. The compound showed no visible signs of physical dependence or constipation in mice. In 
addition, it produced less respiratory depression than morphine. Most mixed MOR / DOR opioids reported 
in the literature are peptides and thereby systemically inactive. Our approach utilizing a multicomponent 
reaction has the promise to deliver potent and efficacious small-molecule analgesics with potential clinical 
utility. 
Keywords: Ugi reaction, Multicomponent reactions, Mu-Delta, opioid analgesics, Carfentanil 
Introduction 
Opioids are the most widely used drugs for the treatment of moderate to severe, chronic pain. 
The most commonly used compound of this class is the epoxymorphinan alkaloid morphine.1 
Morphine (1) and its semi-synthetic analogs based on the same scaffold exhibit their analgesic 
properties through the activation of the three major opioid receptors: mu (MOR), delta (DOR) 
and kappa (KOR).2 Unfortunately, the activation of these receptors, particularly MOR, also 
causes significant side effects3, including respiratory depression, constipation, tolerance, 
physical dependence, and substance abuse.4 A great increase in analgesic potency is achieved 
by using aryl anilido piperidines including fentanyl (2) and carfentanil (3); however, the problem 
of severe side effects remains unsolved by this approach (Figure 1).5 
 
Figure 1. Structures of commonly used opioid analgesics and the proposed carfentanil amides. 
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One possible way to overcome MOR-mediated adverse effects is to synthesize mixed partial 
agonists or compounds with mixed MOR agonist / DOR antagonist properties.6 Previous studies 
have shown that tolerance and dependence to morphine can be reversed by DOR antagonists 
without sacrificing analgesic potency.7 Co-administration of DOR agonists with MOR agonists 
increases the potency and efficacy of MOR agonists as well.8 Similarly, partial activation of 
multiple opioid receptors by a single ligand could produce analgesia without MOR-mediated 
side-effects. Most of the previously reported MOR/DOR mixed agonists are peptides, which 
have somewhat limited relevance from a clinical utility viewpoint.9 Systemically active 
peptidomimetics and non-peptide small molecules have also been reported with a similar 
pharmacological profile.10 An example of a mixed agonist small molecule is SoRI 9409, which 
showed a preferable side effect profile to morphine. However, SoRI 9409 produced limited 
antinociception in thermal pain models, thereby limiting its potential therapeutic value.11 
We substituted the ester moiety with an amide to synthesize carfentanil amide analogs 
(Figure 1, R=alkyl, carbocycle) and determined if they were analgesics with improved side effect 
profiles compared to morphine. The only compound that has been reported in this series is a 
primary amide (R=H).12 To the best of our knowledge, there is no precedence in the literature for 
the synthesis and systematic pharmacological characterization of further carfentanil amides. Our 
inspiration to use carfentanil as a template to synthesize mixed MOR/DOR ligands came from a 
paper from the Portoghese group on fentanyl (structurally closely related to carfentanil). In 
rhesus monkeys, fentanyl analgesia was attenuated by the selective DOR antagonist naltrindole, 
implicating a role for DOR in mediating analgesia of this essentially MOR-selective compound.13 
To assemble the carfentanil scaffold in one step, we turned our attention to multicomponent 
reactions. Multicomponent reactions (MCRs) allow for rapid synthesis of drug-like compound 
libraries by combining three or more reagents into a single product in one step.14 Recently, we 
have reported a novel MCR between 2-aminophenol, ketones and isocyanides to generate a 
diverse library of heterocyclic drug-like scaffolds.15 In the present work, four-component Ugi 
reactions were carried out between N-alkylpiperidones, aniline, propionic acid and an array of 
aliphatic isocyanides. The reaction has previously been used to synthesize a carfentanil 
precursor16 and bivalent ligands.17 We herein report the synthesis and pharmacological 
characterization of novel carfentanil amide analogs. The synthesized derivatives were 
characterized using receptor binding and analgesia assays. The lead compound N-cycloheptyl-
1-phenylethyl-4-(N-phenylpropionamido)piperidine-4-carboxamide (7) was subjected to detailed 
pharmacological studies. This analgesic is a mixed MOR agonist/ DOR partial agonist that does 
not produce physical dependence or constipation in mice.  
Results and Discussion 
Chemistry 
A series of carfentanil amides (4-13) were synthesized using the well-known Ugi reaction 
from commercially available starting materials (Scheme 1). In this particular work, we varied the 
amide substituent of carfentanil amides using various commercially available linear, branched 
and cyclic isocyanides. A ketone with N-cyclopropylmethyl substituent was also employed in the 
same manner. The N-cyclopropylmethyl group is primarily responsible for the MOR-antagonistic 
nature of the clinically used epoxymorphinan antagonist naltrexone. The desired carfentanil 
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amides were isolated in moderate to good yields. The use of Ugi reactions to access carfentanil-
based scaffolds makes diversification library-friendly because of the commercial availability of 
numerous carboxylic acids, amines and isocyanides. 
 
 
Scheme 1. Synthesis of carfentanil amides 4-13. 
Pharmacology 
All synthesized compounds were characterized in in vitro radioligand binding assays in cell 
lines stably transfected with murine MOR, DOR, and KOR. Analogs with N-cyclopropylmethyl 
(12, 13) displayed low affinity across all opioid receptors (Ki > 100 nM), whereas analogs with N-
phenylethyl substituents (4-11) showed moderate to high affinity. As expected, all carfentanil 
amides competed MOR with high affinity (Ki < 10 nM). Most analogs had low affinity (Ki > 100 
nM) for KOR except 5 and 6 with cyclopropyl and cyclohexyl groups at the isocyanide-derived 
amide moiety, respectively. Three compounds, 6 (R2=cyclohexyl), 7 (R2=cycloheptyl) and 11 
(R2=adamantyl) had DOR affinity of less than 10 nM. We were interested in studying the 
pharmacology of compounds with affinity at MOR and DOR. Therefore, 7 was selected for 
further pharmacological evaluation because its affinity for DOR was the highest among all 
synthesized compounds (Table 1). 
Table 1. Summary of in vitro and in silico modeled receptor binding and in vivo tail-flick analgesiaa 
 
   
Ki Ki Ki Ki Ki  
Compd R1 R2 
MOR-CHO 
(nM) 
MOR in 
silico 
(nM) 
DOR-CHO 
(nM) 
DOR in 
silico 
(nM) 
KOR-CHO 
(nM) 
In vivo
c
 
ED50 (mg/kg) 
4 phenylethyl cyclopropyl 10.3 ± 5.1 13.79 >100 54.73 87.6 ± 29 0.78 ± 0.26 
5 phenylethyl cyclopentyl 29.4 ± 15 4.29 90.7 ± 23 50.58 >100 9.92 ± 0.08 
6 phenylethyl cyclohexyl 0.84 ± 0.34 0.66 2.65 ± 0.32 44.60 0.44 ± 0.05 3.10 ± 0.19 
7 phenylethyl cycloheptyl 2.66 ± 1.3 3.80 8.90 ± 7.7 7.90 >100 10.0 ± 0.00  
8 phenylethyl butyl 21.1 ± 11 13.38 87.9 ± 4.8 244.5 >100 >10 
9 phenylethyl t-butyl 2.73 ± 2.2 3.65 71.2 ± 8.7 251.0 >100 1.09 ± 0.05 
10 phenylethyl isoamyl 27.0 ± 20 24.15 27.0 ± 3.6 120.4 >100 >10 
11 phenylethyl adamantyl 25.0 ± 9.8 0.88 8.83 ± 0.63 7.65 >100 >10 
12 CPMb cyclohexyl >100 
 
>100       
 
>100 >10 
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13 CPMb t-butyl >100   >100   >100 >10 
DAMGO 
  
3.34±0.43d 
     
Morphine 
  
4.6±1.81d 
    
5d 
U50,488H 
      
0.73±0.32d 
 
 
DPDPE 
    
1.39±0.67d 
   
aCompetition studies were performed with the indicated compounds against 125 I-BNtxA (0.1 nM) in membranes from 
CHO cells stably expressing the indicated cloned mouse opioid receptors. Ki values were calculated from the IC50 
values18 and represent the means ± SEM of at least three independent replications. In silico Inhibitory constants were 
calculated from the binding free energies obtained from docking (vide infra) according to the following equation: ∆H = 
RT ln Ki. 
125IBNtxA KD values for MOR, KOR, DOR sites were 0.11, 0.03 and 0.24, respectively. 
bCPM = 
cyclopropylmethyl. cAnalgesia was determined using the radiant heat tail-flick technique on CD-1 mice as described in 
the Supporting Information. dValues from literature reference 19. 
In vitro [35S]GTPγS functional assays were carried out on 7, and it was found to be a full 
agonist at MOR (EC50 = 158.7 ± 33 nM, %stimulation = 90.3 ± 0.72) compared with the 
prototypic MOR agonist DAMGO at 100 nM, and a partial agonist at DOR (EC50 = 42.8 ± 12 nM, 
%stimulation = 62.3 ± 9.8) compared with the prototypic DOR agonist DPDPE at 100 nM. 7 is 
about 15-fold less potent an agonist than DAMGO (EC50 = 10.16 ± 2.5 nM) and 1.75-fold less 
potent than DPDPE (EC50= 24.61 ± 7.7 nM) (Table 2). 
Table 2. Opioid receptor efficacy of compound 7a 
Compd 
EC50 (nM) Emax (% stimulation) 
MOR DOR MOR DOR 
7 158.7 ±33.85 42.8 ± 11.56 90.3 ± 0.7 62.3 ± 9.82 
DPDPE ndb 24.61 ± 7.7 
  
DAMGO 10.16 ± 2.5 ndb 
  aEfficacy data were obtained using agonist induced stimulation of [35S]GTPγS binding assay. Efficacy is represented 
as EC50 (nM) and percent maximal stimulation relative to standard agonist DAMGO (MOR), DPDPE (DOR), or 
U50,488H (KOR) at 100 nM. All values are expressed as the mean ± SEM of three separate assays performed in 
triplicate. bNot determined. 
All compounds were also evaluated in tail-flick analgesia assays with the drug given 
subcutaneously in CD1 mice. Some compounds were inactive, whereas 4-7 and 9 showed 
analgesia at the highest given dose of 10 mg/kg. The lack of in vivo analgesic response to 12 
and 13 was not surprising given that these analogs did not possess any appreciable binding 
affinity to opioid receptors. Three compounds in the series (4, 6, 9) were more potent than 
morphine (ED50 ~5 mg/kg, sc).
19 The analgesic ED50 values of 5 and our compound of interest 7 
(ED50 = 10 mg/kg, sc) was about 2-fold lower than that of morphine (Table 1, Figure 2A). 7 was 
next characterized in in vivo antagonism assays. The analgesia of 7 was partially blocked by the 
MOR selective antagonist beta-FNA (40 mg/kg, sc) and DOR selective antagonist naltrindole 
(NTI, 20 mg/kg, sc), suggesting a role of both MOR and DOR in mediating the analgesia. This is 
consistent with our in vitro [35S]GTPγS functional assay results (Figure 2B).  
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 Figure 2. Pharmacology of 7. (A) Analgesia: Cumulative dose-response curves were carried out on groups of mice (n 
= 10) with 7 at the indicated doses (s.c.) and analgesia tested 30 min later at peak effect.  The ED50 value was 10 ± 0 
mg/kg in CD1 mice by using the radiant heat tail-flick assay. (B) Sensitivity of 7 to opioid antagonists: Groups of mice 
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(n = 10) received a fixed dose of 7 (15 mg/kg, s.c.) alone or with β-FNA (40 mg/kg, s.c.) or NTI (20 mg/kg, s.c.). β-FNA 
was given 24h before 7 whereas NTI was given 15 min before 7. Tail flick analgesia was measured 30 min after 
dosing with 7. Similar results were observed in two independent replications. 7 analgesia is partially antagonized by 
both β-FNA and NTI (ANOVA followed by Bonferroni multiple comparison test (p < 0.05). (C) Respiratory rate. 
Animals were randomly assigned to receive saline (n = 5), 7 (40 mg/kg, n = 5), or morphine (20 mg/kg, n = 5). Each 
animal’s baseline average breath rate was measured every 5 min for 25 min before drug injection, and breath rates 
after drug injection are expressed as a percent of baseline. 7 did not depress respiratory rate and was not significantly 
different from saline at any time point, whereas morphine decreased respiratory depression in comparison with both 
saline and 7 (p < 0.05) as determined by repeated-measures ANOVA followed by Bonferroni multiple-comparison test. 
(D) Physical dependence. Groups of mice (n ≥ 10) received either morphine (10 mg/kg s.c.) or 7 (1 mg/kg s.c.) until 
they showed complete tolerance. They were then challenged with naloxone. Naloxone precipitated a profound 
withdrawal syndrome in the morphine-treated animals, as shown by the number of jumps per 15 min, which was 
significantly greater than that in the morphine or 7 controls (i.e., given no antagonist) or in 7 mice given naloxone. 
Mice chronically administered 7 showed no significant difference from controls when challenged by naloxone (1 mg/kg 
s.c.).  (E) Gastrointestinal (GI) transit. Groups of mice (n = 10) received saline, morphine (5 mg/kg), or 7 (20 and 50 
mg/kg) before receiving an oral dose of 0.2 mL of charcoal meal (2.5% gum tragacanth in 10% activated charcoal in 
water) by gavage. Animals were sacrificed 30 min later, and the distance traveled by charcoal was measured. 7 did 
not lower GI transit significantly compared with saline (P < 0.05) and the effect was significantly lower than that of 
morphine (P < 0.05) as determined by ANOVA followed by Tukey’s multiple-comparison test. 
We next looked at the side-effect profile of 7 in mouse models of respiratory depression (RD) 
and physical dependence. At doses 4xED50 (40 mg/kg, sc) 7 did show some signs of RD, 
although it was significantly lower than RD caused by the same relative dose of morphine 
(Figure 2C). Chronic administration of traditional opioids leads to both tolerance and physical 
dependence. Daily administration of morphine (10 mg/kg s.c., 2xED50) produced a diminishing 
analgesic response with no analgesia by day 5. These chronically morphine-treated mice were 
both tolerant and physically dependent. Naloxone precipitated a profound withdrawal syndrome 
in morphine treated-mice. Chronic dosing of 7 also produced tolerance. However, 7-tolerant 
mice challenged with naloxone demonstrated fewer withdrawal symptoms. Figure 2D indicates 
they jumped fewer times than morphine treated mice. In addition, there were no signs of 
diarrhea in 7-tolerance mice challenged with naloxone. Another serious side-effect associated 
with clinically used mu analgesics is constipation. At doses 2xED50 (20 mg/kg) and 5xED50 (50 
mg/kg) 7 showed no signs of constipation, while morphine caused constipation at its ED50 dose 
(Figure 2E). Thus, according to mouse models of GI transit and physical dependence. the full 
MOR agonist and partial DOR agonist 7 may be useful in negating multiple major side-effects 
seen with classical MOR analgesics such as morphine. We hope to optimize the structure of this 
carfentanil amide scaffold to maintain receptor affinities and MOR agonism, while reducing the 
DOR efficacy to attain a MOR agonist / DOR antagonist based pharmacophore to further 
attenuate respiratory depression. The utilization of Ugi chemistry to diversify the amine and 
carboxylic acid ends with commercially available reagents makes further derivatives readily 
accessible. 
 
In Silico Receptor Binding 
Docking of carfentanil amides 4-11 to the MOR and the in silico predictions of inhibitory 
constants (Table 1) were most successful when the original crystal structure was used as the 
target. Dockings to the experimentally derived DOR structure were unsuccessful, as only 
unrealistic or high binding free energy receptor ligand complexes were obtained. Docking to a 
molecular dynamics (MD) simulation-derived DOR model however resulted in accurate 
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reproduction of experimental receptor binding data. This suggests that changes in the receptor 
conformation introduced by crystal packing and antagonist binding could be different for MOR 
and DOR. Blind docking results showed that compounds 4-11 also bind to the same cavity 
where alkaloid-type ligands20 as well as peptides21 were found to bind (Figure 3). This 
contradicts a previous hypothesis which states that chemically different ligand types have 
separate binding sites. However, binding orientations of each ligand type were found to be 
different both in the case of MOR and DOR ligands. Because of its exceptional properties 
demonstrated in the pharmacological assays, binding orientation and interactions of 7 with MOR 
and DOR were analyzed in more detail. Compound 7 was found to form more contacts with the 
binding pockets than the alkaloid antagonists showed in the crystal structures. Three of the MOR 
side-chains which were found to interact with the ligand in the crystal structure do not form 
contacts with 7 in the docked complexes; however four new contacts are formed with other 
amino acids (Figure 4A). In the case of 7 binding to the DOR, two native contacts were missing 
and six new contacts were observed compared to the crystal complex (Figure 4B). Therefore, 
binding and functional properties of different ligands may not necessarily involve more than one 
binding site.22 Instead, ligand-specific interactions23 may trigger (or arrest) conformational 
changes of the receptor upon binding. 
 
 
Figure 3. Docked complexes of 7 and MOR (A); 7 and DOR (B). N- and C-terminal tails are omitted for clarity. 
Compounds were blind-docked to full sequence MOR and DOR receptor models derived from experimental structures 
(pdb codes: 4DKL and 4EJ4, respectively) and molecular dynamics simulations. Dockings were performed using the 
Autodock 4.2 software, having the side chains of the binding site residues and all ligand torsions kept flexible. 
Inhibitory constants were calculated from the binding free energies obtained from docking according to the following 
equation: ∆H = RT ln Ki. For complete description of the applied methods of model building and docking see 
Supporting Information 
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 Figure 4. Amino acid side chains of MOR (A) and DOR (B) that participate in interactions with 7. Side chains 
observed in the crystal structures to take part in receptor-ligand interactions but do not form contacts with 7 in the 
docked complexes are depicted in orange. Non-polar hydrogens are omitted for clarity. 
Conclusions 
Our hypothesis was to synthesize a compound with high affinity for MOR and DOR and low 
affinity for KOR using a robust, library-friendly method. Ten compounds based on carfentanil 
using the Ugi multicomponent reaction were synthesized. Our lead was found to be a full agonist 
at MOR and partial agonist at DOR. It showed moderate analgesic affinity compared with 
morphine, sc. This compound showed some respiratory depression. However, it produced no 
physical dependence or inhibition of GI transit in mouse models. To our knowledge, this is the 
first time an opioid scaffold with mixed MOR/DOR profile has been synthesized using the Ugi 
MCR. While there are plenty of examples of dual MOR/DOR agonists and MOR agonism-DOR 
antagonism based ligands in the literature,24 in vivo side-effect profile evaluation of full MOR 
agonist partial DOR agonist compounds has not been reported previously. It seems likely that 
mixed MOR/DOR agonists can negate at least two of the important side-effects of morphine, 
namely physical dependence and constipation. Future diversification of analogs will aim to study 
the SAR at the amine and carboxylic acid end using the chemistry presented in this manuscript. 
The utilization of Ugi chemistry to diversify the amine and carboxylic acid residues with 
commercially available substrates in a library friendly manner makes this approach even more 
attractive and readily accessible.  
Methods 
All chemicals were purchased from Sigma-Aldrich Chemicals and Alfa Aesar, and were used 
without further purification. Reaction mixtures were purified by Silica Flash chromatography on 
E. Merck 230–400 mesh silica gel 60 using a Teledyne ISCO CombiFlash Rf instrument with UV 
detection at 280 and 254 nm. RediSep Rf silica gel normal phase columns were used with a 
gradient of 0–10% MeOH in DCM. The yields reported are isolated yields. IR spectra were 
recorded on a Bruker Optics Tensor 27 FTIR spectrometer with peaks reported in cm–1. NMR 
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spectra were recorded on Bruker Avance III 500, Avance III 600 with DCH CryoProbe 
instruments. NMR spectra were processed with MestReNova software (ver. 6.1.1.). Chemical 
shifts are reported in parts per million (ppm) relative to residual solvent peaks rounded to the 
nearest 0.01 for proton and 0.1 for carbon (CDCl3 
1H: 7.26, 13C: 77.3; CD3OD 
1H: 3.31, 13C: 49.0; 
DMSO-d6 
13C: 39.5). Peak multiplicity is reported as follows: s – singlet, d – doublet, t – triplet, q 
– quartet, m – multiplet. Coupling constants (J) are expressed in Hz. Mass spectra were 
obtained at the MSKCC Analytical Core Facility on a Waters Acuity SQD LC MS by electrospray 
(ESI) ionization.  High resolution mass spectra were obtained on a Waters Acuity Premiere XE 
TOF LC-MS by electrospray ionization. Accurate masses are reported for the molecular ion 
[M+H]+. A reversed-phase HPLC using a Perkin-Elmer LC pump series 200 and a 785A UV/VIS 
detector (214 nM) was used. A Varian microsorb MV 100−5 reversed-phase column (5 µm × 4.6 
mm × 250 mm) with the mobile phases being 0.1% TFA in water and 0.1% TFA in ACN with a 
gradient elution at a flow rate of 1 mL/min was used. 
Chemical synthesis 
General procedure for the Ugi multicomponent reaction (synthesis of 4-13): 
To a solution of aniline (40.1 µl, 0.44 mmol) in methanol (2.2 mL) were added isocyanide (0.44 
mmol, 1 equiv), substituted 4-piperidone (0.44 mmol, 1 equiv), and propionic acid (32.89 µl, 0.44 
mmol, 1 equiv) and stirred at 55 ºC for 18 hours. Solvent was removed under reduced pressure. 
The reaction mixture was purified by silica gel flash chromatography (0-15% MeOH in DCM). 
Receptor-Binding Assays:   
Competition-binding assays in CHO cells stably expressing  MOR, DOR or KOR were performed 
at 25°C in potassium phosphate buffer (50 mM; pH 7.4), with the inclusion of MgSO4 (5 mM) in 
the MORassays. All competition assays were carried out using 125I-BNtxA as described.25 
Specific binding was defined as the difference between total binding and nonspecific binding, 
determined in the presence of levallorphan (8 µM). Protein concentrations were between 30-40 
µg/mL and incubation times were 90 minutes. Protein concentration was determined as 
described by Lowry et al.26 using bovine serum albumin as the standard.  
Tail Flick Analgesia Assays:  
Male CD-1 mice (25-35 g; Charles River Breeding Laboratories, Wilmington, MA) were 
maintained on a 12-hr light/dark cycle with Purina rodent chow and water available ad libitum.  
Mice were housed in groups of five until testing. All animal experiments were reviewed and 
approved by the Institutional Animal Care and Use Committee of Memorial Sloan Kettering 
Cancer Center. Analgesia was determined using the radiant heat tail-flick technique27 using a 
machine from Ugo Basile (model number 37360). The intensity was set to achieve a baseline 
between 2-3 sec. The latency to withdraw the tail from a focused light stimulus was measured 
electronically using a photocell. Baseline latencies (2.0-3.0 sec) were determined before 
experimental treatments for all animals. Post-treatment tail-flick latencies were determined as 
indicated for each experiment, and a maximal latency of 10 sec for tail-flick was used to 
minimize tissue damage. Analgesia was defined quantally as a doubling, or greater, of the 
baseline latency.  Similar results were obtained analyzing the data in a graded response manner 
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as % Maximum Possible Effect [(observed latency − baseline latency)/(maximal latency − 
baseline latency)]. Analgesic ED50 values and confidence limits were determined using non-
linear regression analysis GraphPad Prism (San Diego, CA). Drugs were given subcutaneously 
and cumulative dose-response experiments carried out with at least two independent assays 
with each group (n=10). The combined results presented as the ED50 with SEM of replicates 
presented.   
[35S]GTPγS-Binding Assay: 
[35S]GTPγS binding was performed on membranes prepared from transfected cells in the 
presence and absence of the indicated opioid for 60 min at 30°C in the assay buffer (50 mM 
Tris-HCl, pH 7.4, 3 mM MgCl2, 0.2 mM EGTA, and 10 mM NaCl) containing 0.05nM [
35S]GTPγS 
and 30 uM GDP, as previously reported.26 After the incubation, the reaction was filtered through 
glass-fiber filters (Whatman Schleicher & Schuell, Keene, NH) and washed three times with 3 ml 
of ice-cold 50 mM Tris-HCl, pH 7.4, on a semiautomatic cell harvester. Filters were transferred 
into vials with 3 ml of Liquiscent (National Diagnostics, Atlanta, GA), and the radioactivity in vials 
was determined by scintillation spectroscopy in a Tri-Carb 2900TR counter (PerkinElmer Life 
and Analytical Sciences). Basal binding was determined in the presence of GDP and the 
absence of drug. Maximum stimulation was determine in the presence of 100nM DAMGO, 
DPDPE, and U50,488h for MOR, DOR, and KOR, respectively. 
Respiratory Depression Assay 
Respiratory rate was assessed in awake, freely moving, adult male CD1 mice with the MouseOx 
pulse oximeter system (Starr Life Sciences), as previously reported.27 Each animal was 
habituated to the device for 30 min and then tested. A 5-s average breath rate was assessed at 
5-min intervals. A baseline for each animal was obtained over a 25-min period before drug 
injection, and testing began at 15 min post-injection and continued for a period of 35 min. 
Groups of mice (n = 5) were treated subcutaneously with either saline or morphine (20 mg/kg) or 
7 (40 mg/kg). Morphine and 7 were given at doses approximately four times its analgesic ED50. 
Groups were compared with repeated-measures ANOVA followed by Bonferroni multiple-
comparison test. 
Gastrointestinal transit 
Groups of mice (n = 10) received saline, morphine (5 mg/kg), or 7 (20 and 50 mg/kg) before 
receiving an oral dose of 0.2 mL of charcoal meal (2.5% gum tragacanth in 10% activated 
charcoal in water) by gavage. Animals were sacrificed 30 min later, and the distance traveled by 
charcoal was measured. 7 did not lower transit significantly compared with saline (P > 0.05) as 
determined by ANOVA followed by Tukey’s multiple-comparison test. 
Receptor docking 
Full sequence target structures of the human MOR and DOR receptors for docking studies were 
built using the recently deposited crystal strucures of the homologuous murine opioid receptors30 
as templates (PDB codes: 4DKL and 4EJ4, respectively). Homology modeling of the 
transmembrane region and intra- and extracellular loops was performed using the Modeller 9.11 
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software package. The missing intracellular loop and N- and C-terminal tails were built using the 
loop module of Modeller. 100 structures were generated for both receptors and ranked by the 
modeller energy function. The best ranking models of each receptor were then subjected to 200 
ns molecular dynamics simulations to obtain relaxed, equlibrated, ligand-free inactive structures 
of the receptors, exempt of strains occurrently introduced by crystal lattice forces and/or induced 
fit binding of antagonists.  
200ns long molecular dynamics (MD) simulations in the NPγT ensemble and explicit, hydrated 
DOPC membrane bilayer environment31 were performed using the Gromacs 4.5.4 software 
package and the Amber ff02 and gAFF force fields. The temperature, pressure and surface 
tension were set to 310 K, 1 bar and 440 bar nm, respectively. The time step was set to 2 fs and 
non-bonded interactions were calculated using the PME method with all cutoff values set at 12 
Å. The resultant trajectories were analyzed by clustering to identify dominantly occurring spatial 
arranegements of the amino acids which were shown to interact with ligands in the crystal 
structures. Clustering was performed using the g_cluster utility and the gromos method32 with 1 
Å of RMSD similarity cut-off, fitting all heavy atoms of the binding site residues. The geometry of 
the transmembrane region of unliganded DOR was found to change more compared to that of 
the MOR during the course of MD simulations indicating a more intense reverse rearrangement 
of DOR upon ligand removal. For each receptor, representative structures of the five most 
populated structural families, as well as the original crystal structure, complemented with the 
missing loops were used for docking studies.  
Dockings were performed with the Autodock 4.2 software, where the side chains of the binding 
site residues were kept flexible and all ligand torsions were allowed. Compounds 4-11 were 
docked using the Lamarckian genetic algorithm in a grid volume large enough to cover the whole 
receptor region accessible from the extracellular side. The grid spacing was set to 0.375 Å and 
1000 dockings were done for all receptor models. To check the validity of the applied methods 
and receptor models, well characterized, selective alkaloid and peptide agonists of both 
receptors were docked for comparison. Inhibitory constants were calculated from the binding 
free energies obtained from docking according to the following equation: ∆H = RT ln Ki. 
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